PACB
2026/09/22
USPacific Biosciences of California
| Side | Reported Price | Filled | Portfolio changes |
|---|---|---|
| Buy Increase | 1.36 188,508 | +1.09% Holding |
Disclaimer: The content is compiled based on publicly available market information. Accuracy, timeliness, and completeness of the data are not guaranteed. It is for reference purposes only and does not constitute any investment advice.
284
Report
Login to post
- Shivaya·09-24 17:32PACB is facing severe debt burdens, high cash burn, and negative shareholder equity, making it a distressed turnaround play rather than a fundamentally sound long-term hold.LikeReport
- CINDYTAN·09-24 09:32[Happy]LikeReport
- Deposit·09-24 09:08👍LikeReport
